Provided by Tiger Trade Technology Pte. Ltd.

Alexander's

236.96
-0.4300-0.18%
Volume:43.29K
Turnover:10.32M
Market Cap:1.21B
PE:43.08
High:241.01
Open:237.80
Low:236.96
Close:237.39
52wk High:260.84
52wk Low:189.05
Shares:5.11M
Float Shares:2.13M
Volume Ratio:0.79
T/O Rate:2.04%
Dividend:17.99
Dividend Rate:7.59%
EPS(TTM):5.50
EPS(LYR):5.50
ROE:19.74%
ROA:3.32%
PB:11.09
PE(LYR):43.11

Loading ...

Alexander's Inc. zahlt Quartalsdividende von 4,50 US-Dollar je Aktie

Reuters
·
Feb 05

Alexander's Inc. Declares $4.50 Quarterly Dividend

Reuters
·
Feb 05

Earning Preview: Alexander's Q4 revenue is expected to decrease by 3.26%, and institutional views are limited and cautious

Earnings Agent
·
Feb 02

What Atlas Arteria (ASX:ALX)'s Q4 Toll Revenue Growth Means For Shareholders

Simply Wall St.
·
Feb 02

ALX Oncology announces major underwritten public equity offering

TIPRANKS
·
Jan 30

ALX Oncology Announces Pricing of Underwritten Offering

GlobeNewswire
·
Jan 30

New Data Demonstrate CD47 Expression Level Helps Predict Response to ALX Oncology’s Evorpacept in Combination with Ziihera (zanidatamab-hrii) in Advanced HER2-Positive Breast Cancer

GlobeNewswire
·
Jan 30

ALX Oncology Expands Inducement Equity Plan for Hiring

TIPRANKS
·
Jan 22

Alexander's Inc. Publishes Update to Financial Calendar

Reuters
·
Jan 21

ALX Oncology first patient dosed in Phase 2 ASPEN-09-Breast trial

TIPRANKS
·
Jan 08

ALX Oncology Advances Separate Clinical Trials Evaluating Investigational CD47-Inhibitor Evorpacept and Novel EGFR-Targeted Antibody-Drug Conjugate ALX2004

GlobeNewswire
·
Jan 08

Alexander’s Completes Restructuring of Retail Loan at 731 Lexington Avenue

GlobeNewswire
·
Dec 29, 2025

Alexander’s (ALX) Valuation After Rego Park II Refinancing and New $175 Million Interest-Only Loan

Simply Wall St.
·
Dec 11, 2025

Alexander’s Completes $175 Million Refinancing of Rego Park Ii

THOMSON REUTERS
·
Dec 09, 2025

Alexander's Inc. Secures $175 Million Refinancing for Rego Park II Shopping Center

Reuters
·
Dec 09, 2025

ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting

GlobeNewswire
·
Dec 07, 2025

Henderson Land Development Files Directors List to HKEX

Reuters
·
Dec 01, 2025

PT International Development Corporation Files Directors List to HKEX

Reuters
·
Nov 30, 2025

ALX Oncology to Present at Upcoming Investor Conferences

GlobeNewswire
·
Nov 19, 2025

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and 60 Degrees Pharmaceuticals, Inc. (SXTP)

TIPRANKS
·
Nov 17, 2025